# Goldman Sachs BDC, Inc.: financial statements, quarterly

GSBD · NYSE · CIK 1572694 · [Other](/sectors/other.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/gsbd.md) · [Financials](/companies/gsbd/financials.md) · [Filings](/companies/gsbd/filings.md) · [Insiders](/companies/gsbd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/gsbd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Income tax | $m | [1.5](/filings/0000950170-24-123412.md) | [1.7 d](/filings/0000950170-25-029231.md) | [1.1](/filings/0000950170-25-067098.md) | [1.2](/filings/0000950170-25-105134.md) | [1.5](/filings/0001193125-25-269840.md) | [1.5 d](/filings/0000950170-25-029231.md) | [1.3](/filings/0000950170-25-067098.md) | [0.9](/filings/0000950170-25-105134.md) | [0.9](/filings/0001193125-25-269840.md) | not reported | not reported | not reported |
| Net income | $m | [51.6](/filings/0000950170-24-123412.md) | [50.6 d](/filings/0001193125-26-077458.md) | [42.5](/filings/0000950170-25-067098.md) | [(54.2)](/filings/0000950170-25-105134.md) | [37.1](/filings/0001193125-25-269840.md) | [37.5 d](/filings/0001193125-26-077458.md) | [31.6](/filings/0001193125-26-212431.md) | [39.3](/filings/0001193125-26-338331.md) | [24.7](/filings/0001193125-25-269840.md) | [23.7 d](/filings/0001193125-26-077458.md) | [(13.6)](/filings/0001193125-26-212431.md) | [23.7](/filings/0001193125-26-338331.md) |
| Diluted EPS | $ per share | [0.47](/filings/0000950170-24-123412.md) | not reported | [0.39](/filings/0000950170-25-067098.md) | [(0.47)](/filings/0000950170-25-105134.md) | [0.32](/filings/0001193125-25-269840.md) | not reported | [0.27](/filings/0001193125-26-212431.md) | [0.34](/filings/0001193125-26-338331.md) | [0.22](/filings/0001193125-25-269840.md) | not reported | [(0.12)](/filings/0001193125-26-212431.md) | [0.21](/filings/0001193125-26-338331.md) |
| Basic EPS | $ per share | [0.47](/filings/0000950170-24-123412.md) | not reported | [0.39](/filings/0000950170-25-067098.md) | [(0.47)](/filings/0000950170-25-105134.md) | [0.32](/filings/0001193125-25-269840.md) | not reported | [0.27](/filings/0001193125-26-212431.md) | [0.34](/filings/0001193125-26-338331.md) | [0.22](/filings/0001193125-25-269840.md) | not reported | [(0.12)](/filings/0001193125-26-212431.md) | [0.21](/filings/0001193125-26-338331.md) |

- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:ProfitLoss, us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [76.6](/filings/0000950170-23-060336.md) | [52.4](/filings/0000950170-25-029231.md) | [52.3](/filings/0000950170-24-054635.md) | [61.6](/filings/0000950170-24-094144.md) | [53.0](/filings/0000950170-24-123412.md) | [61.8](/filings/0001193125-26-077458.md) | [82.8](/filings/0000950170-25-067098.md) | [108](/filings/0000950170-25-105134.md) | [115](/filings/0001193125-25-269840.md) | [43.2](/filings/0001193125-26-338331.md) | [41.9](/filings/0001193125-26-212431.md) | [14.4](/filings/0001193125-26-338331.md) |
| Total assets | $m | [3,558](/filings/0000950170-23-060336.md) | [3,523](/filings/0000950170-25-029231.md) | [3,547](/filings/0000950170-24-054635.md) | [3,629](/filings/0000950170-24-094144.md) | [3,545](/filings/0000950170-24-123412.md) | [3,603](/filings/0001193125-26-077458.md) | [3,504](/filings/0000950170-25-067098.md) | [3,410](/filings/0000950170-25-105134.md) | [3,385](/filings/0001193125-25-269840.md) | [3,383](/filings/0001193125-26-338331.md) | [3,343](/filings/0001193125-26-212431.md) | [3,288](/filings/0001193125-26-338331.md) |
| Total liabilities | $m | [1,958](/filings/0000950170-23-060336.md) | [1,921](/filings/0000950170-25-029231.md) | [1,916](/filings/0000950170-24-054635.md) | [2,033](/filings/0000950170-24-094144.md) | [1,959](/filings/0000950170-24-123412.md) | [2,031](/filings/0001193125-26-077458.md) | [1,956](/filings/0000950170-25-067098.md) | [1,897](/filings/0000950170-25-105134.md) | [1,930](/filings/0001193125-25-269840.md) | [1,960](/filings/0001193125-26-338331.md) | [1,973](/filings/0001193125-26-212431.md) | [1,930](/filings/0001193125-26-338331.md) |
| Long-term debt | $m | [1,878](/filings/0000950170-23-060336.md) | [1,827](/filings/0000950170-25-029231.md) | [1,831](/filings/0000950170-24-054635.md) | [1,944](/filings/0000950170-24-094144.md) | [1,878](/filings/0000950170-24-123412.md) | [1,926](/filings/0001193125-26-077458.md) | [1,868](/filings/0000950170-25-067098.md) | [1,797](/filings/0000950170-25-105134.md) | [1,841](/filings/0001193125-25-269840.md) | [1,875](/filings/0001193125-26-338331.md) | [1,898](/filings/0001193125-26-212431.md) | [1,850](/filings/0001193125-26-338331.md) |
| Shareholders' equity | $m | [1,601](/filings/0000950170-24-123412.md) | [1,602](/filings/0001193125-26-077458.md) | [1,632](/filings/0000950170-25-105134.md) | [1,596](/filings/0001193125-25-269840.md) | [1,586](/filings/0001193125-25-269840.md) | [1,573](/filings/0001193125-26-338331.md) | [1,548](/filings/0001193125-26-338331.md) | [1,513](/filings/0001193125-26-338331.md) | [1,455](/filings/0001193125-25-269840.md) | [1,423](/filings/0001193125-26-338331.md) | [1,370](/filings/0001193125-26-338331.md) | [1,358](/filings/0001193125-26-338331.md) |

- Cash and equivalents: us-gaap:Cash
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [160 d](/filings/0000950170-24-123412.md) | [82.8 d](/filings/0001193125-26-077458.md) | [7.0](/filings/0000950170-25-067098.md) | [(122) d](/filings/0000950170-25-105134.md) | [104 d](/filings/0001193125-25-269840.md) | [13.1 d](/filings/0001193125-26-077458.md) | [134](/filings/0001193125-26-212431.md) | [174 d](/filings/0001193125-26-338331.md) | [47.2 d](/filings/0001193125-25-269840.md) | [(29.9) d](/filings/0001193125-26-077458.md) | [10.4](/filings/0001193125-26-212431.md) | [53.6 d](/filings/0001193125-26-338331.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [26.5 d](/filings/0001193125-25-269840.md) | [15.0 d](/filings/0001193125-26-077458.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [102](/filings/0000950170-23-060336.md) | [105](/filings/0000950170-24-054635.md) | [109](/filings/0000950170-24-094144.md) | [110](/filings/0000950170-24-123412.md) | [110](/filings/0000950170-25-067098.md) | [114](/filings/0000950170-25-105134.md) | [117](/filings/0001193125-25-269840.md) | [117](/filings/0001193125-26-212431.md) | [117](/filings/0001193125-26-338331.md) | [114](/filings/0001193125-25-269840.md) | [113](/filings/0001193125-26-212431.md) | [113](/filings/0001193125-26-338331.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 112,569,067 at 2026-08-05, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338331.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.